Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by kristian7on May 08, 2018 11:39pm
246 Views
Post# 28002305

RE:RE:Wittman - partnership

RE:RE:Wittman - partnershipHi Wittmann , Just saw your post commenting mine of a few days ago. I agree that things were done in the past that unfortunately made the o/s float where it is today  .. Too easy to blame PL , but harder to give him credit that if this is still alive and I’m on the side of those that think; it’s because of him ... . Now , IF in fact there’s a 4050 global partnership to be announced ( for real... based on all the rumors and the solid alstrom data of course  ) why would it only be seen like a regular pipe ? Depending on the agreement of course, but if it provides good cash upfront plus the whole phase 3 costs plus milestones money and X % royalties on the sales ... and obviously the backing of a big Pharma..., all this without Pg ‘s nearby approval in Pg deficiency and upcoming applications.... Don’t you think that this company isn’t worth a minimum of  $3.50 ( 2 $G) in the coming year ( which makes this a great return from 71 cents)  ; the value  that we were at in 2016 ( maybe over valued at the time I must say ) But hey , we could’ve been bought out at $5 back then... who knows ??? Can’t look back, but what’s ahead is the game now ???  I still think it’s a valuable investment .
Bullboard Posts